Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains

Structure

Volumn 21, Issue 7, 2013, Pages 1214-1224

  Schmitz, Karl R ^a,c   Bagchi, Atrish ^a   Roovers, Rob C ^b,d   Van Bergen En Henegouwen, Paul M P ^b   Ferguson, Kathryn M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Merus Biopharmaceuticals   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; MONOCLONAL ANTIBODY; NANOBODY;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN BINDING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; CRYSTALLOGRAPHY, X-RAY; CYSTINE; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SINGLE-DOMAIN ANTIBODIES;

EID: 84879823647     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2013.05.008     Document Type: Article

References (55)

1. J. Abbott, and D. Beckett Cooperative binding of the Escherichia coli repressor of biotin biosynthesis to the biotin operator sequence Biochemistry 32 1993 9649 9656
2. P.D. Adams, P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, and R.W. Grosse-Kunstleve PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66 2010 213 221
3. D. Alvarado, D.E. Klein, and M.A. Lemmon ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor Nature 461 2009 287 291
4. J. Baselga, and C.L. Arteaga Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J. Clin. Oncol. 23 2005 2445 2459
5. A. Beck, T. Wurch, C. Bailly, and N. Corvaia Strategies and challenges for the next generation of therapeutic antibodies Nat. Rev. Immunol. 10 2010 345 352
6. D. Beckett, E. Kovaleva, and P.J. Schatz A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation Protein Sci. 8 1999 921 929
7. S. Bouyain, P.A. Longo, S. Li, K.M. Ferguson, and D.J. Leahy The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand Proc. Natl. Acad. Sci. USA 102 2005 15024 15029
8. A.T. Brünger, P.D. Adams, G.M. Clore, W.L. DeLano, P. Gros, R.W. Grosse-Kunstleve, J.S. Jiang, J. Kuszewski, M. Nilges, and N.S. Pannu Crystallography & NMR system: A new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54 1998 905 921
9. A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, D.J. Leahy, M.A. Lemmon, M.X. Sliwkowski, C.W. Ward, and S. Yokoyama An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors Mol. Cell 12 2003 541 552
10. CCP4 (Collaborative Computational Project, Number 4) The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
11. D.R. Davies, and G.H. Cohen Interactions of protein antigens with antibodies Proc. Natl. Acad. Sci. USA 93 1996 7 12
12. E. De Genst, K. Silence, K. Decanniere, K. Conrath, R. Loris, J. Kinne, S. Muyldermans, and L. Wyns Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies Proc. Natl. Acad. Sci. USA 103 2006 4586 4591
13. A. Desmyter, T.R. Transue, M.A. Ghahroudi, M.H. Thi, F. Poortmans, R. Hamers, S. Muyldermans, and L. Wyns Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme Nat. Struct. Biol. 3 1996 803 811
14. C.D. Emmerson, E.J. van der Vlist, M.R. Braam, P. Vanlandschoot, P. Merchiers, H.J. de Haard, C.T. Verrips, P.M. van Bergen en Henegouwen, and E. Dolk Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH PLoS ONE 6 2011 e26299
15. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132
16. K.M. Ferguson, P.J. Darling, M.J. Mohan, T.L. Macatee, and M.A. Lemmon Extracellular domains drive homo- but not hetero-dimerization of erbB receptors EMBO J. 19 2000 4632 4643
17. K.M. Ferguson, M.B. Berger, J.M. Mendrola, H.S. Cho, D.J. Leahy, and M.A. Lemmon EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization Mol. Cell 11 2003 507 517
18. L.O. Gainkam, L. Huang, V. Caveliers, M. Keyaerts, S. Hernot, I. Vaneycken, C. Vanhove, H. Revets, P. De Baetselier, and T. Lahoutte Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT J. Nucl. Med. 49 2008 788 795
19. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, G.O. Lovrecz, H.J. Zhu, F. Walker, M.J. Frenkel, and P.A. Hoyne Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α Cell 110 2002 763 773
20. G.N. Gill, T. Kawamoto, C. Cochet, A. Le, J.D. Sato, H. Masui, C. McLeod, and J. Mendelsohn Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity J. Biol. Chem. 259 1984 7755 7760
21. W.J. Gullick Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers Br. Med. Bull. 47 1991 87 98
22. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman, and R. Hamers Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
23. M.M. Harmsen, and H.J. De Haard Properties, production, and applications of camelid single-domain antibody fragments Appl. Microbiol. Biotechnol. 77 2007 13 22
24. E.G. Hofman, M.O. Ruonala, A.N. Bader, D. van den Heuvel, J. Voortman, R.C. Roovers, A.J. Verkleij, H.C. Gerritsen, and P.M. van Bergen En Henegouwen EGF induces coalescence of different lipid rafts J. Cell Sci. 121 2008 2519 2528
25. P.H. Huang, A.M. Xu, and F.M. White Oncogenic EGFR signaling networks in glioma Sci. Signal. 2 2009 re6
26. S. Jähnichen, C. Blanchetot, D. Maussang, M. Gonzalez-Pajuelo, K.Y. Chow, L. Bosch, S. De Vrieze, B. Serruys, H. Ulrichts, and W. Vandevelde CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells Proc. Natl. Acad. Sci. USA 107 2010 20565 20570
27. S. Koide Engineering of recombinant crystallization chaperones Curr. Opin. Struct. Biol. 19 2009 449 457
28. A. Koide, V. Tereshko, S. Uysal, K. Margalef, A.A. Kossiakoff, and S. Koide Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope J. Mol. Biol. 373 2007 941 953
29. M.C. Lawrence, and P.M. Colman Shape complementarity at protein/protein interfaces J. Mol. Biol. 234 1993 946 950
30. S. Li, K.R. Schmitz, P.D. Jeffrey, J.J. Wiltzius, P. Kussie, and K.M. Ferguson Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 2005 301 311
31. S. Li, P. Kussie, and K.M. Ferguson Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8 Structure 16 2008 216 227
32. P. Liu, S. Bouyain, C. Eigenbrot, and D.J. Leahy The ErbB4 extracellular region retains a tethered-like conformation in the absence of the tether Protein Sci. 21 2012 152 155
33. A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read Phaser crystallographic software J. Appl. Cryst. 40 2007 658 674
34. S. Muyldermans, T. Atarhouch, J. Saldanha, J.A. Barbosa, and R. Hamers Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains Protein Eng. 7 1994 1129 1135
35. S. Muyldermans, C. Cambillau, and L. Wyns Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains Trends Biochem. Sci. 26 2001 230 235
36. V.K. Nguyen, A. Desmyter, and S. Muyldermans Functional heavy-chain antibodies in Camelidae Adv. Immunol. 79 2001 261 296
37. H. Ogiso, R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, J.H. Kim, K. Saito, A. Sakamoto, M. Inoue, M. Shirouzu, and S. Yokoyama Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains Cell 110 2002 775 787
38. S. Oliveira, G.A. van Dongen, M. Stigter-van Walsum, R.C. Roovers, J.C. Stam, W. Mali, P.J. van Diest, and P.M. van Bergen en Henegouwen Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody Mol. Imaging 11 2012 33 46
39. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode C.W. Carter Jr. R.M. Sweet, Macromolecular Crystallography, part A 1997 Academic Press New York 307 326
40. J.S. Philo, K.H. Aoki, T. Arakawa, L.O. Narhi, and J. Wen Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction Biochemistry 35 1996 1681 1691
41. R.C. Roovers, T. Laeremans, L. Huang, S. De Taeye, A.J. Verkleij, H. Revets, H.J. de Haard, and P.M. van Bergen en Henegouwen Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies Cancer Immunol. Immunother. 56 2007 303 317
42. R.C. Roovers, M.J. Vosjan, T. Laeremans, R. el Khoulati, R.C. de Bruin, K.M. Ferguson, A.J. Verkleij, G.A. van Dongen, and P.M. van Bergen en Henegouwen A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth Int. J. Cancer 129 2011 2013 2024
43. D. Saerens, G.H. Ghassabeh, and S. Muyldermans Single-domain antibodies as building blocks for novel therapeutics Curr. Opin. Pharmacol. 8 2008 600 608
44. J.D. Sato, T. Kawamoto, A.D. Le, J. Mendelsohn, J. Polikoff, and G.H. Sato Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors Mol. Biol. Med. 1 1983 511 529
45. J. Schmiedel, A. Blaukat, S. Li, T. Knöchel, and K.M. Ferguson Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization Cancer Cell 13 2008 365 373
46. K.R. Schmitz, and K.M. Ferguson Interaction of antibodies with ErbB receptor extracellular regions Exp. Cell Res. 315 2009 659 670
47. P. Schuck Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling Biophys. J. 78 2000 1606 1619
48. J. Steyaert, and B.K. Kobilka Nanobody stabilization of G protein-coupled receptor conformational states Curr. Opin. Struct. Biol. 21 2011 567 572
49. F.W. Studier Protein production by auto-induction in high density shaking cultures Protein Expr. Purif. 41 2005 207 234
50. N. Sugawa, A.J. Ekstrand, C.D. James, and V.P. Collins Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas Proc. Natl. Acad. Sci. USA 87 1990 8602 8606
51. B.M. Tijink, T. Laeremans, M. Budde, M. Stigter-van Walsum, T. Dreier, H.J. de Haard, C.R. Leemans, and G.A. van Dongen Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology Mol. Cancer Ther. 7 2008 2288 2297
52. I. Vaneycken, M. D'huyvetter, S. Hernot, J. De Vos, C. Xavier, N. Devoogdt, V. Caveliers, and T. Lahoutte Immuno-imaging using nanobodies Curr. Opin. Biotechnol. 22 2011 877 881
53. A.J. Wong, J.M. Ruppert, S.H. Bigner, C.H. Grzeschik, P.A. Humphrey, D.S. Bigner, and B. Vogelstein Structural alterations of the epidermal growth factor receptor gene in human gliomas Proc. Natl. Acad. Sci. USA 89 1992 2965 2969
54. B. You, and E.X. Chen Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab J. Clin. Pharmacol. 52 2012 128 155
55. H. Zhang, A. Berezov, Q. Wang, G. Zhang, J. Drebin, R. Murali, and M.I. Greene ErbB receptors: from oncogenes to targeted cancer therapies J. Clin. Invest. 117 2007 2051 2058